EMPA-KIDNEY baseline infographic
For healthcare professionals only. This page is for educational purposes only with the intent to communicate the EMPA-KIDNEY trial results. Empagliflozin is not indicated for the treatment of patients with chronic kidney disease in the Philippines. Please refer to the local approved product information for the current indication. Date: February 2023 RIN No. SC-PH-04498
SC-PH-04471
%product_id%